Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma - Takeaways - MDSpire

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma

  • By

  • Joseph B. Parker

  • Richard W. Joseph

  • Vera J. Suman

  • Yiyi Yan

  • Ruqin Chen

  • June 10, 2026

  • 0 min

Share

  • 1

    The trial evaluated the combination of topical imiquimod and pembrolizumab for unresectable cutaneous metastatic melanoma.

  • 2

    Seven patients participated, with a median treatment exposure of 8 cycles and an objective response rate of 57.1%.

  • 3

    Among the participants, 42.9% achieved a complete response, while 1 had a partial response and 2 had stable disease.

  • 4

    The 7-month progression-free survival rate was 57.1%, indicating promising preliminary efficacy of the treatment.

  • 5

    The combination therapy was found to be feasible and safe, with mostly grade 1 toxicities reported.

Original Source(s)

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma

  • by Joseph B. Parker, Richard W. Joseph, Vera J. Suman, Yiyi Yan, Ruqin Chen

  • June 10, 2026

Related Content

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer

Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review

Multidisciplinary team care and outcomes in FNCLCC grade 3 soft tissue sarcoma: a propensity score–matched and weighted cohort study